Analysts Offer Predictions for Lonza Group FY2025 Earnings

Key Points

• William Blair has raised its FY2025 earnings per share (EPS) estimates for Lonza Group to $2.07, up from the previous forecast of $2.03, with the consensus estimate for the current year being $1.88.
• Lonza Group has recently increased its dividend to $0.1054 per share, reflecting a 0.15% dividend yield, which is an increase from the previous $0.10.
• As of the latest trading session, Lonza Group's stock was down 1.8% and is currently trading around $71.16.

Lonza Group Ag (OTCMKTS:LZAGY - Free Report) - William Blair raised their FY2025 EPS estimates for Lonza Group in a report issued on Wednesday, July 23rd. William Blair analyst M. Smock now expects that the company will post earnings per share of $2.07 for the year, up from their prior estimate of $2.03. The consensus estimate for Lonza Group's current full-year earnings is $1.88 per share. William Blair also issued estimates for Lonza Group's FY2026 earnings at $2.45 EPS.

Lonza Group Stock Up 2.4%

Shares of Lonza Group stock traded up $1.70 during midday trading on Friday, hitting $71.96. 12,124 shares of the company traded hands, compared to its average volume of 85,925. The company has a current ratio of 1.52, a quick ratio of 1.04 and a debt-to-equity ratio of 0.45. The firm's fifty day moving average price is $69.81 and its 200-day moving average price is $66.70. Lonza Group has a 12 month low of $55.57 and a 12 month high of $73.29.

Lonza Group Increases Dividend

The company also recently declared a dividend, which was paid on Friday, May 30th. Stockholders of record on Thursday, May 15th were given a $0.1054 dividend. The ex-dividend date of this dividend was Wednesday, May 14th. This represents a dividend yield of 0.15%. This is an increase from Lonza Group's previous dividend of $0.10.

Lonza Group Company Profile

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments.